Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score. (Q50921836)

25 March 2018

title

Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score. (English)

1 reference

25 March 2018

author name string

Bradley M Turner

1

1 reference

25 March 2018

Kristin A Skinner

2

1 reference

25 March 2018

Ping Tang

3

1 reference

25 March 2018

Mary C Jackson

4

1 reference

25 March 2018

Nyrie Soukiazian

5

1 reference

25 March 2018

Michelle Shayne

6

1 reference

25 March 2018

Alissa Huston

7

1 reference

25 March 2018

Marilyn Ling

8

1 reference

25 March 2018

David G Hicks

9

1 reference

25 March 2018

publication date

1 May 2015

1 reference

25 March 2018

published in

Modern Pathology

1 reference

25 March 2018

volume

28

1 reference

25 March 2018

issue

7

1 reference

25 March 2018

page(s)

921-931

1 reference

25 March 2018

cites work

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

Chemotherapy use for hormone receptor-positive, lymph node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

Risk factors for breast cancer according to estrogen and progesterone receptor status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

Pathological work up of the primary tumor: getting the proper information out of it.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

Molecular evolution of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

Use of Oncotype DX in Women with Node-Positive Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

Histopathologic variables predict Oncotype DX recurrence score

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

Impact of progesterone receptor semiquantitative immunohistochemical result on Oncotype DX recurrence score: a quality assurance study of 1074 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

Semi-quantitative immunohistochemical assay versus oncotype DX(®) qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

Proliferation (Ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptor-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

A Lower Allred Score for Progesterone Receptor Is Strongly Associated With a Higher Recurrence Score of 21-Gene Assay in Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

Development of the 21-gene assay and its application in clinical practice and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor‐positive, HER2‐normal, grade II, lymph node‐negative breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

Precision oncology in breast cancer: better than ever, or less than before?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer--a problem still to be solved

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

Recommendations for Improved Standardization of Immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2015.50

Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer

21 January 2018

1 reference

12 December 2020

Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?

1 reference

12 December 2020

Molecular pathology of breast cancer: what a pathologist needs to know

1 reference

12 December 2020

Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing

1 reference

12 December 2020

Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases

1 reference

12 December 2020

Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update

1 reference

12 December 2020

HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy

1 reference

12 December 2020

Is the Oncotype DX assay necessary in strongly estrogen receptor-positive breast cancers?

1 reference

12 December 2020

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

1 reference

12 December 2020

Interobserver agreement among pathologists for semiquantitative hormone receptor scoring in breast carcinoma

1 reference

12 December 2020

[Cost-effectiveness of a chemotherapy predictive test].

1 reference

12 December 2020

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).

1 reference

12 December 2020

Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing?

1 reference

12 December 2020

The challenge and importance of standardizing pre-analytical variables in surgical pathology specimens for clinical care and translational research

1 reference

12 December 2020

Nottingham-defined mitotic score: comparison with visual and image cytometric phosphohistone H3 labeling indices and correlation with Oncotype DX recurrence score.

1 reference

12 December 2020

10.1038/MODPATHOL.2015.50

Identifiers

DOI

1 reference

25 March 2018

Dimensions Publication ID

1038476233

0 references

1 reference

25 March 2018